Background
==========

The role of molecular markers for prediction of osteoarthritis (OA) progression is not yet defined. Pentosidine, one of the well-characterized advanced glycation endproducts, may be a candidate.

Objectives
==========

To study the role of pentosidine as a marker of knee OA, as a marker of progression of knee OA, and for correlation of pentosidine in serum and synovial fluid and correlation with other markers.

Methods
=======

Pentosidine was estimated by our own HLPC method \[[@B1]\], and cartilage digomeric matrix protein (COMP) by an original sandwich ELISA with monoclonal antibodies 16-F 12 and 17 C 10 \[[@B2]\]. MMP-9, TIMP and YKL-40 were estimated by commercial ELISA kits. Joint space width was measured in the narrowest point of the tibiofemoral compartment by 0.1 caliper and magnifying glass.

Results
=======

Eighty-nine patients with knee OA were included in the study and were followed for 2 years. The paired samples of serum and synovial fluid were obtained from 48 patients in second study. The joint space narrowing in 2 years was 0.4 ± 0.79 mm. The patients with knee OA had higher initial serum values of pentosidine than controls (*P*= 0.04) and also of TIMP (*P*= 0.04), MMP-9 (*P*= 0.02) and COMP (*P*= 0.05). The patients with initially higher serum levels of pentosidine had more rapid radiological progression than controls (*r*= 0.30), and the same was true for hyaluronic acid (*r*= 0.56). Serum pentosidine levels correlated with synovial fluid pentosidine levels (*r*^2^= 0.78). Mild correlation occurred between synovial fluid pentosidine and COMP levels (*r*^2^= 0.11, *P*\< 0.05).

Conclusions
===========

Serum pentosidine levels may be a new molecular marker for prediction of OA progression.
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